NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/30/2020 12:07
Last Report Issued 07/16/2015 12:06

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1826SP
Patient ID 1826SP
Chain 15001738
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 15001738

Received 07/15/2015 12:50

Sample ID 15001738-001
Matrix Serum or Plasma
Patient Name 1826SP
Patient ID 1826SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
1826SP Dronabinol, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
11-Hydroxy Delta-9 THC	None Detected	ng/mL	1.0	
Synonym(s): Active Metabolite				
Dronabinol undergoes extensive first-pass hepatic metabolism. 11-OH-THC is the principal active metabolite of dronabinol. Concentrations of both parent drug and metabolite peak at approximately 0.5 to 4 hours after oral dosing and decline over several days.				
Maximum 11-OH-THC plasma concentrations for 6 subjects were determined during and after 5-day dosing sessions with 7.5 mg dronabinol/day. Maximum concentrations (Cmax) ranged from 1.3 - 2.6 ng/mL at 1.5 to 107 hours (Tmax). 11-OH-THC was not detected in one subject.				
Delta-9 Carboxy THC	None Detected	ng/mL	5.0	
Synonym(s): Inactive Metabolite				

Results for sample 15001738-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Sample ID 15001738-001
Matrix Serum or Plasma
Patient Name 1826SP
Patient ID 1826SP

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Dronabinol undergoes extensive first-pass hepatic metabolism. THCC is an inactive dronabinol metabolite. Maximum THCC plasma concentrations for 6 subjects were determined during and after 5-day dosing sessions with 7.5 mg dronabinol/day. Maximum concentrations (Cmax) ranged from 10 - 43 ng/mL at 107 hours (Tmax).				
Delta-9 THC	None Detected	ng/mL	0.50	
Synonym(s): Marinol®; Dronabinol Dronabinol, the active ingredient in Marinol® Capsules, is synthetic delta-9-tetrahydrocannabinol (delta-9-THC). The capsules contain 2.5 mg, 5 mg, or 10 mg dronabinol. Dronabinol demonstrates reversible effects on appetite, mood, cognition, memory and perception. These phenomena appear to be dose-related, increasing in frequency with higher dosages, and subject to great interpatient variability. After oral administration, Dronabinol has an onset of action of approximately 0.5 to 1 hours and peak effect at 2 to 4 hours, but the appetite stimulant effect of Dronabinol may continue for 24 hours or longer after administration. Maximum THC plasma concentrations for 6 subjects were determined during and after 5-day dosing sessions with 7.5 mg dronabinol/day. Maximum concentrations (Cmax) ranged from 0.6 - 3.8 ng/mL at 6.5 to 107 hours (Tmax).				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.